Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 25, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
July 25, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
July 24, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
July 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
July 17, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
July 16, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
June 20, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
June 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
June 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
June 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
June 03, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
June 03, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
June 02, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
RCUS
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
June 01, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
RCUS
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
May 31, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Provides Update on Phase 3 TROPiCS-04 Study
May 30, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
May 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
May 18, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
May 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
ACLX
GILD
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
May 07, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
April 30, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
April 26, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces First Quarter 2024 Financial Results
April 25, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
April 08, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
March 28, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
XLO
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
March 11, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
MRK
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.